We have located links that may give you full text access.
Significance of Number and Localization of Positive Core Biopsies for the Identification of Prostate Cancer Eligible for Active Surveillance.
Analytical and Quantitative Cytopathology and Histopathology 2016 Februrary
OBJECTIVE: Prostate cancer (PCa) patients fulfilling the Epstein criteria for insignificant disease are eligible for the treatment option of active surveillance (AS). Using the combined histological and cytological grading (Gleason/Helpap score), we aimed to investigate the significance of biopsy localization and tumor involvement in core needle biopsies as discriminators for insignificant cancer.
STUDY DESIGN: Primary prostate biopsies of 1,285 patients were analyzed by the combined histological and cytological grading with regard to biopsy localization and tumor involvement per core. For patients diagnosed with pT2a stage PCa, core needle biopsies were further compared with the corresponding radical prostatectomy (RP) specimens.
RESULTS: According to the combined histological and cytological grading, 95% of low-grade PCas (Gleason score 6/2a, prognostic grading group I) presented with a tumor involvement of < 10% in 1 core biopsy, whereas intermediate-grade tumors (prognostic grading group 2) displayed dissimilar tumor localization in 1 or both lobes with higher tumor volume.
CONCLUSION: Our results indicate that the combined Gleason/Helpap grading may contribute to a more reliable identification of insignificant PCa with the option of AS. Ancillary criteria include the limitation of tumor involvement to < 10% per core, localized in 1 or 2 adjacent biopsies in only 1 lobe. Under this presupposition, > 90% of insignificant carcinomas concurred with low-grade PCa and stage pT2a tumors with negative margins after RP.
STUDY DESIGN: Primary prostate biopsies of 1,285 patients were analyzed by the combined histological and cytological grading with regard to biopsy localization and tumor involvement per core. For patients diagnosed with pT2a stage PCa, core needle biopsies were further compared with the corresponding radical prostatectomy (RP) specimens.
RESULTS: According to the combined histological and cytological grading, 95% of low-grade PCas (Gleason score 6/2a, prognostic grading group I) presented with a tumor involvement of < 10% in 1 core biopsy, whereas intermediate-grade tumors (prognostic grading group 2) displayed dissimilar tumor localization in 1 or both lobes with higher tumor volume.
CONCLUSION: Our results indicate that the combined Gleason/Helpap grading may contribute to a more reliable identification of insignificant PCa with the option of AS. Ancillary criteria include the limitation of tumor involvement to < 10% per core, localized in 1 or 2 adjacent biopsies in only 1 lobe. Under this presupposition, > 90% of insignificant carcinomas concurred with low-grade PCa and stage pT2a tumors with negative margins after RP.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app